Efficacy of careHPV™ human papillomavirus screening versus conventional cytology tests for the detection of precancerous and cancerous cervical lesions among women living with HIV‐1 in Lao People's Democratic Republic

Abstract

This is an open access article under the terms of the Creat ive Commo ns Attri bution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Diagnostic accuracy of cervical cancer screening strategies for high-grade cervical intraepithelial neoplasia (CIN2+/CIN3+) among women living with HIV: A systematic review and meta-analysis

“… 25 , 29 , 30 , 32 , 36 , 37 , 39 , 41 , 42 , 45 , 47 , 48 , 51 , 53 . Twenty-eight studies evaluated any HR-HPV DNA test method for CIN2+ 24 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 45 , 46 , 49 , 50 , 51 , 54 , 55 , 56 , 57 , 60 and 18 for CIN3+; 25 , 28 , 29 , 30 , 33 , 36 , 37 , 39 , 41 , 42 , 45 , 47 , 49 , 50 , 51 , 53 , 60 , 61 these included Hybrid Capture II (HC-II; 16 studies); 27 , 29 , 31 , 34 , 35 , 36 , 37 , 40 ...…”

“…Thirteen studies enrolled WLHIV attending cervical cancer screening in outpatient gynaecology clinics, 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 whereas 21 studies recruited WLHIV attending HIV clinics. 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 Two studies recruited WLHIV with a prior positive screen-test (HPV-positive) 58 , 59 and two studies included a combination of women attending primary care and women referred to colposcopy because of positive HPV test and/or abnormal cytology. 60 , 61 The median age of enrolled women within studies ranged from 30 to 50 years (age range: 19 to 68 years).…”

“…No studies evaluated automated visual evaluation (AVE) methods. Twenty-three studies evaluated cervical cytology for CIN2+: 18, 13 and 16 using threshold ASCUS+, 25 , 26 , 29 , 32 , 36 , 37 , 39 , 40 , 41 , 42 , 45 , 46 , 47 , 48 , 51 , 53 , 56 , 57 LSIL+ 25 , 29 , 34 , 36 , 37 , 39 , 42 , 45 , 46 , 47 , 48 , 51 , 53 and HSIL+ 25 , 26 , 29 , 30 , 32 , 34 , 36 , 37 , 39 , 42 , 45 , 47 , 48 , 51 , 52 , 53 , respectively; 14 for CIN3+. 25 , 29 , 30 , 32 , 36 , 37 , 39 , 41 , 42 , 45 , 47 , 48 , 51 , 53 .…”

Human papillomavirus testing on self‐collected samples to detect high‐grade cervical lesions in rural Bhutan: The REACH‐Bhutan study

“…The presence of human DNA in all specimens was confirmed by βglobin PCR analysis as quality control for the extraction procedure and subsequent PCR. HR-HPV positivity was assessed by GP5+/6+−mediated PCR 14 followed by hybridization of PCR products in an enzyme immunoassay (EIA) with an oligoprobe cocktail for detection of 13 HR-HPV types (16,18,31,33,35,39,45,51,52,56,58,59, and 68). Genotyping of EIA-positive samples was subsequently conducted by luminex hybridization of GP5+/6+−PCR products as described previously.…”

Review of the Standard and Advanced Screening, Staging Systems and Treatment Modalities for Cervical Cancer

“…Currently, there are FDA-approved and validated HPV tests, including the Hybrid Capture 2 (HC2) assay (Qiagen, Gaithersburg, MD, USA), based on the DNA-Probe-Hybrid immunoassay technique; CervistaHPV HR and Cervista™ (Hologic, San Diego, CA, USA) HPV16/18, based on DNA-probe technology; the Cobas 4800 HPV test (Roche Molecular Systems Inc., Pleasanton, CA, USA) and the PCR-based BD Onclarity™ HPV assay (BD Diagnostics, Sparks, MD, USA); the APTIMA HPV assay (Hologic, San Diego, CA, USA), based on RNA capture and the amplification of HPV RNA [ 56 ]; and the Luminex Genotyping GP HR (Diassay, The Netherlands) immunoassay, as well as the reverse-hybridization-based INNO-LiPA HPV Genotyping (Fujirebio, Gent, Belgium) [ 57 ]. The target regions for these tests are the L1, E6, or E7 genes encoded by HPV, with a sensitivity of about 80% [ 58 ]. While these qualitative tests allow the detection of HPV genotypes in samples, advancement has made possible the inclusion of the use of the automated platform.…”